{'52WeekChange': -0.52821314,
 'SandP52WeekChange': 0.0644362,
 'address1': '35 Gatehouse Drive',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 3.15,
 'askSize': 800,
 'averageDailyVolume10Day': 372050,
 'averageVolume': 180882,
 'averageVolume10days': 372050,
 'beta': None,
 'beta3Year': None,
 'bid': 3.01,
 'bidSize': 4000,
 'bookValue': 2.084,
 'category': None,
 'circulatingSupply': None,
 'city': 'Waltham',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 3.16,
 'dayLow': 3.01,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -0.38,
 'enterpriseToRevenue': 2.606,
 'enterpriseValue': 18239360,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 3.0462856,
 'fiftyTwoWeekHigh': 9.25,
 'fiftyTwoWeekLow': 1.75,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 4754543,
 'forwardEps': -1.48,
 'forwardPE': -2.0337837,
 'fromCurrency': None,
 'fullTimeEmployees': 48,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.24014,
 'heldPercentInstitutions': 0.65038,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/entasistx.com',
 'longBusinessSummary': 'Entasis Therapeutics Holdings Inc., a clinical-stage '
                        'biopharmaceutical company, focuses on the discovery, '
                        'development, and commercialization of novel '
                        'antibacterial products to treat serious infections '
                        'caused by multi-drug resistant gram-negative bacteria '
                        'in the United States. It is involved in developing '
                        'Sulbactam-durlobactam (SUL-DUR), a novel IV '
                        'antibiotic that has completed Phase II clinical trial '
                        'for the treatment of multi-drug resistant '
                        'Acinetobacter infections; Zoliflodacin, a novel '
                        'orally administered molecule that has completed Phase '
                        'II clinical trial for the treatment of uncomplicated '
                        'gonorrhea; ETX0282CPDP, an oral drug that is in Phase '
                        'I clinical trial for the treatment of urinary tract '
                        'infections; and ETX0462, a drug candidate from NBP '
                        'platform that is in pre-clinical stage for the '
                        'treatment of multidrug-resistant Gram-negative '
                        'infections. The company has collaboration agreements '
                        'with Zai Lab (Shanghai) Co., Ltd. for developing '
                        'SUL-DUR. Entasis Therapeutics Holdings Inc. was '
                        'incorporated in 2018 and is based in Waltham, '
                        'Massachusetts.',
 'longName': 'Entasis Therapeutics Holdings Inc.',
 'market': 'us_market',
 'marketCap': 82147712,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_558232165',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -46175000,
 'nextFiscalYearEnd': 1640908800,
 'open': 3.02,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '781 810 0120',
 'previousClose': 3.045,
 'priceHint': 4,
 'priceToBook': 1.4443377,
 'priceToSalesTrailing12Months': 11.735388,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 3.16,
 'regularMarketDayLow': 3.01,
 'regularMarketOpen': 3.02,
 'regularMarketPreviousClose': 3.045,
 'regularMarketPrice': 3.02,
 'regularMarketVolume': 135765,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 27291600,
 'sharesPercentSharesOut': 0.00059999997,
 'sharesShort': 17710,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 23586,
 'shortName': 'Entasis Therapeutics Holdings I',
 'shortPercentOfFloat': 0.00090000004,
 'shortRatio': 0.08,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'ETTX',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -3.498,
 'twoHundredDayAverage': 3.5270505,
 'volume': 135765,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.entasistx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02451'}